免疫功能正常与免疫抑制患者血液EBV DNA检测的临床效用:单中心经验
该研究回顾性分析了2022年11月至2023年间成人EBV核酸扩增检测阳性的患者,共3560次检测中187次(5.3%)阳性,涉及124例独特成人患者(51例免疫功能正常,73例免疫抑制)。
要点
- EBV NAAT阳性率低(5.3%),在免疫抑制患者中更常影响治疗决策。
- 脓毒症/休克和非特异性病毒综合征时送检EBV NAAT对临床管理影响极小(0-2%)。
- 移植后和恶性肿瘤筛查/监测时送检EBV NAAT对临床管理影响显著(37-49%)。
核心结论
- EBV NAAT检测在免疫功能正常个体中较少影响临床管理,但在免疫抑制患者中影响显著,尤其是移植后或恶性肿瘤筛查/监测者。
- 应针对特定人群和指征进行靶向检测,以优化资源利用和成本效益。
研究设计与样本
- 回顾性图表审查,纳入2022年11月至2023年成人EBV NAAT阳性患者,记录人口学、检测指征、EBV相关诊断、实验室结果及检测是否影响治疗。
- 共3560次EBV NAAT检测,187次(5.3%)阳性,代表124例独特成人患者(51例免疫功能正常,73例免疫抑制)。
主要发现
- EBV再激活是两组中最常见的诊断,免疫功能正常者其次为急性EBV感染,免疫抑制者其次为非移植后淋巴增殖性疾病恶性肿瘤。
- 检测对临床管理的影响因指征而异:脓毒症/休克和非特异性病毒综合征为0%至2%,移植后和恶性肿瘤筛查/监测为37%至49%。
关键数值与推荐
- EBV NAAT阳性率:187/3560(5.3%)。
- 脓毒症/休克和非特异性病毒综合征指征下检测影响临床管理0%至2%。
- 移植后和恶性肿瘤筛查/监测指征下检测影响临床管理37%至49%。
临床怎么用
- 对于免疫功能正常患者,避免在脓毒症/休克或非特异性病毒综合征时常规送检EBV NAAT。
- 对于免疫抑制患者,尤其是移植后或恶性肿瘤筛查/监测者,EBV NAAT检测可能显著影响临床管理。
局限性
- 回顾性单中心研究,样本量有限(124例阳性患者),可能存在选择偏倚。
- 未报告检测对临床管理影响的具体定义或评估方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Epstein-Barr virus (EBV) causes different clinical presentations in immunocompetent and immunocompromised persons, and thus indications for testing vary between these populations. We reviewed our institution's EBV DNA testing across these populations to understand its clinical utility and appropriateness. METHODS: We conducted a retrospective chart review of adult patients with positive EBV nucleic acid amplification (NAAT) testing from November 2022 to 2023. We recorded demographics, indications for testing, EBV-related diagnosis, laboratory results, and whether testing influenced patient treatment. RESULTS: Of 3560 EBV NAAT tests, 187 (5.3%) were positive, representing 124 unique adult patients (51 immunocompetent and 73 immunocompromised). Reactivation of EBV was the most common diagnosis in both populations, followed by acute EBV infection in the immunocompetent and non-posttransplant lymphoproliferative disorder malignancies in the immunocompromised. In immunocompromised patients, positive tests led to treatment changes more frequently than in immunocompetent patients (27.4% vs 11.7%, P = .06). Testing affected clinical management in 0% to 2% of cases when sent for sepsis/shock and nonspecific viral syndromes compared to 37% to 49% of cases when sent for posttransplant and malignancy screening/monitoring. DISCUSSION: EBV NAAT testing infrequently influenced clinical management in immunocompetent individuals but had a notable impact in immunocompromised patients, particularly those undergoing posttransplant or malignancy screening. This underscores the need for targeted testing to optimize resource utilization and cost-effectiveness.
引用
- Gupta S, Turbett SE, Klontz E, et al. Clinical utility of EBV DNA testing of blood in immunocompetent and immunocompromised patients: A single-center experience. Am J Clin Pathol. 2025. PMID: 39450750. doi:10.1093/ajcp/aqae143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。